SCHEMBL5288051

SCHEMBL5288051

CC1CN(S(=O)(=O)c2c(Cl)ccc3nonc23)CC(C)O1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.57
NPC1 O15118 2/20 0.57
TLR9 Q9NR96 1/20 0.57
SMN1; SMN2 Q16637 4/20 0.50
TSHR P16473 2/20 0.46
CXCR2 P25025 2/20 0.45
ACLY P53396 1/20 0.43
POLB P06746 1/20 0.41
PKM P14618 1/20 0.41
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5298150 0.84 KMT2A (0.41) KMT2ANPC1TLR9SMN1; SMN2TSHR
SCHEMBL5285381 0.79 KMT2A (0.58) KMT2ANPC1TLR9SMN1; SMN2POLB
SCHEMBL5244644 0.77 KMT2A (0.62) KMT2ANPC1TLR9SMN1; SMN2POLB
SCHEMBL18575963 0.73 KMT2A (0.48) KMT2ANPC1TLR9POLBALDH1A1
SCHEMBL4787717 0.73 TSHR (0.42) KMT2ANPC1TLR9TSHRPOLB
SCHEMBL1022338 0.72 KMT2A (0.46) KMT2ANPC1TLR9POLBALDH1A1
SCHEMBL8159362 0.71 KMT2A (0.58) KMT2ANPC1TLR9POLBALDH1A1
SCHEMBL6392936 0.70 KMT2A (0.48) KMT2ANPC1TLR9TSHRALDH1A1
SCHEMBL5282272 0.70 TSHR (0.51) KMT2ASMN1; SMN2TSHRPOLBALDH1A1
SCHEMBL5281618 0.70 KMT2A (0.49) KMT2ANPC1TLR9POLBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP KMT2A 1303/4885NPC1 1567/4885TLR9 2693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.